DOCS (Doximity, Inc.) Stock Analysis - News

Doximity, Inc. (DOCS) is a publicly traded Healthcare sector company. As of May 20, 2026, DOCS trades at $19.65 with a market cap of $3.62B and a P/E ratio of 15.59. DOCS moved +3.30% today. Year to date, DOCS is -56.53%; over the trailing twelve months it is -62.53%. Its 52-week range spans $17.15 to $85.21. Analyst consensus is buy with an average price target of $26.78. Rallies surfaces DOCS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in DOCS news today?

Doximity Guides 4% FY27 Growth Despite Rapid AI Adoption, Shares Oversold: Doximity reported FY26 revenue growth with margin compression and guided FY27 revenue up just 4% with EBITDA margins pressured by ramped AI investments, despite rapid adoption of its clinical AI tools. Shares tumbled 25.7% over four weeks, becoming technically oversold as analysts raise earnings estimates.

DOCS Key Metrics

Key financial metrics for DOCS
MetricValue
Price$19.65
Market Cap$3.62B
P/E Ratio15.59
EPS$1.27
Dividend Yield0.00%
52-Week High$85.21
52-Week Low$17.15
Volume3.63M
Avg Volume0
Revenue (TTM)$637.78M
Net Income$239.40M
Gross Margin89.75%

Latest DOCS News

Recent DOCS Insider Trades

  • Sitaram Siddharth sold 2.31K (~$59.50K) on May 11, 2026.
  • Wampler Kira Scherer sold 9.00K (~$234.54K) on May 7, 2026.
  • Sitaram Siddharth sold 2.43K (~$51.19K) on Apr 10, 2026.

DOCS Analyst Consensus

21 analysts cover DOCS: 0 strong buy, 9 buy, 12 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $26.78.

Common questions about DOCS

What changed in DOCS news today?
Doximity Guides 4% FY27 Growth Despite Rapid AI Adoption, Shares Oversold: Doximity reported FY26 revenue growth with margin compression and guided FY27 revenue up just 4% with EBITDA margins pressured by ramped AI investments, despite rapid adoption of its clinical AI tools. Shares tumbled 25.7% over four weeks, becoming technically oversold as analysts raise earnings estimates.
Does Rallies summarize DOCS news?
Yes. Rallies summarizes DOCS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is DOCS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DOCS. It does not provide personalized investment advice.
DOCS

DOCS